Rolapitant Reduces Nausea and Vomiting Associated with Cisplatin-Based Chemotherapy

During a press conference at ESMO 2014, Dr Bernardo Leon Rapoport, The Medical Oncology Centre – Rosebank, Johannesburg, South Africa, presents the results of a Phase III study on the use of rolapitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy.

Year of Production:
Running Time:
Color/Sound:

2014
06:10
Color/Sound

Comments are closed.